Our respiratory facilities form part of the Nottingham Clinical Research Facility and include a full suite of laboratories, research tissue repository and easy access to Endoscopy, CT, MRI and other diagnostic facilities.
We have close links on respiratory themes with researchers within other research groupings in the University of Nottingham and Nottingham University Hospitals NHS Trust, such as epidemiology, molecular microbiology, drug discovery, allergy, immunology and child health.
We are part of several major national/international collaborations and work closely with commercial pharma companies and are part of the NIHR NOCRI Translational Research Collaboration (TRC) in inflammatory respiratory disease.
Leading the field in translational molecular diagnostic capabilities. The Nottingham Molecular Pathology Node (NMPN) is one of 6 nodes funded by the Medical Research Council (MRC)and the Engineering and Physical Sciences Research Council (EPSRC) to develop molecular pathology tests which will help deliver better targeted, more effective treatments – known as ‘stratified medicine’ – across a wide range of disease areas.
The NMPN is based at the University of Nottingham Clinical Sciences Building at Nottingham City Hospital.
Our research is one of the original contributors to the NIHR Translational Research Collaboration (TRC) centres. This recognises our expertise in inflammatory respiratory diseases with dedicated infrastructure including, academic and clinical skills, laboratory facilities and a cohort of well-characterised patients on our research database available for clinical development studies.
The NIHR TRC in inflammatory respiratory disease brings together internationally recognised investigators in the UK’s leading centres of excellence to carry out early phase research with industry.
This NIHR TRC carries out outstanding translational research in inflammatory respiratory disease. Together with industry partners, the TRC focuses on early phase clinical research in patients to identify mechanisms of pathophysiology of disease, or to demonstrate proof of concept or evidence of the validity of new discoveries or treatments. The Centre Academic Lead (CAL) is Professor Tim Harrison.
We collaborated in the very first TRC research project to come through the system in 2012 with Italian-based Chiesi Farmaceutici.
The COPD Initiative – COPDMAP – is part of the Medical Research Council (MRC)/Association of British Pharmaceutical Industry (ABRI) Inflammation and Immunology Initiative. It represents the first phase of a new approach in funding by the Medical Research Council, bringing together academics and industry at the earliest stages of development a stratified approach to disease (targeting the right treatments to the right people), enabling effective clinical trials as well as identifying novel biomarkers, mechanisms and targets.